Stock · NSE
GLENMARK
2,305.00▼ 24.00 (-1.03%)Last 2 days · 15m candles25/8/2026, 00:35:14
Open: 2,324.50High: 2,330.20Low: 2,305.00Prev: 2,329.00
VERIFIEDMint Markets·3d★ ON YOUR LIST
Buy or sell: Gift Nifty signals gap-up start, Vaishali Parekh recommends three stocks to buy today — 21 August 2026AI summary· NEUTRAL
- ·Gift Nifty signals a gap-up start for the Indian stock market.
- ·Vaishali Parekh has recommended three stocks for trading today.
- ·The recommended stocks are Hindustan Zinc, DCB Bank, and Glenmark Pharma.
VERIFIEDET Stocks·3d★ ON YOUR LIST
Glenmark Pharmaceuticals among 5 stocks showing bullish RSI upswingAI summary· POSITIVE
- ·Five Nifty500 stocks, including Glenmark Pharmaceuticals, showed a bullish RSI upswing on August 20.
- ·These stocks gained over 4% on the identified date.
- ·An uptrend signal is generated when the RSI value crosses above 50 from below.
VERIFIEDMint Markets·3d★ ON YOUR LIST
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 21 August 2026AI summary· NEUTRAL
- ·Nifty 50 closed at 24,231.85 despite recent losses.
- ·Analysts recommend buying Dixon Technologies.
- ·Analysts recommend buying Glenmark Pharmaceuticals and Eternal shares.
VERIFIEDMint Companies·12d★ ON YOUR LIST
Glenmark Pharma US subsidiary agrees to $15.28 million settlement with Humana in generic drug antitrust caseAI summary· NEUTRAL
- ·Glenmark Pharma's US subsidiary will pay $15.28 million to settle a lawsuit with Humana.
- ·The lawsuit involved allegations of generic drug pricing.
- ·Market allocation was also a point of contention in the litigation.
VERIFIEDET Finance·34d★ ON YOUR LIST
Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn SaldanhaAI summary· POSITIVE
- ·Glenmark expects innovative products to contribute 70% of its revenue in 5-6 years.
- ·The company is developing next-generation products for oncology and complex diseases.
- ·Glenmark aims to become a global oncology powerhouse within ten years, leveraging AI for drug discovery.
VERIFIEDET Finance·34d★ ON YOUR LIST
Glenmark gets USFDA nod for expanded use of RYALTRIS nasal sprayAI summary· POSITIVE
- ·Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray.
- ·The approval expands its use to children aged six to twelve years.
- ·RYALTRIS treats symptoms of seasonal allergic rhinitis and combines antihistamine and corticosteroid.
VERIFIEDET Markets·48d★ ON YOUR LIST
Stocks in news: Adani Enterprises, Cochin Shipyard, IDFC First Bank, Premier Energies, Glenmark PharmaAI summary· NEUTRAL
- ·Cochin Shipyard's offer for sale received strong investor demand on its first day.
- ·Adani Enterprises' US legal case is likely to be dismissed by federal prosecutors.
- ·IDFC First Bank has launched provident fund payment services through its EPFO integration.
VERIFIEDET Stocks·48d★ ON YOUR LIST
Stocks in news: Adani Enterprises, Cochin Shipyard, IDFC First Bank, Premier Energies, Glenmark PharmaAI summary· NEUTRAL
- ·Cochin Shipyard's offer for sale received strong investor demand on its first day.
- ·Adani Enterprises' US legal case is likely to be dismissed by federal prosecutors.
- ·IDFC First Bank has launched provident fund payment services through its EPFO integration.
VERIFIEDMint Companies·48d★ ON YOUR LIST
Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman SaldanhaAI summary· NEUTRAL
- ·Glenmark is pivoting towards global drug innovation with a 10-year plan.
- ·The strategy involves licensing deals, partnerships, and commercialization in emerging markets.
- ·Chairman Glenn Saldanha outlined the company's future direction.
VERIFIEDET Finance·49d★ ON YOUR LIST
Glenmark launches generic Olanzapine injection in USAI summary· NEUTRAL
- ·Glenmark Pharmaceuticals has launched a generic version of Olanzapine injection in the United States.
- ·The injection is a treatment for schizophrenia and bipolar disorder.
- ·This launch aims to expand Glenmark's injectable offerings and institutional market presence.
VERIFIEDMint Markets·83d★ ON YOUR LIST
After a dull Q4, Glenmark Pharma needs a booster shot to growAI summary· NEUTRAL
- ·Glenmark Pharma is focusing on core operational execution for FY27 growth.
- ·The company is looking past one-off licensing gains.
- ·Investors are shifting their focus to operational execution.
VERIFIEDMint Markets·87d★ ON YOUR LIST
Q4 results today: Asian Paints, IndiGo, IREDA, Glenmark Pharma - 131 companies to announce earnings on 29 MayAI summary· NEUTRAL
- ·131 companies, including Asian Paints and IndiGo, will announce their Q4 results on May 29.
- ·Analysts anticipate a weak performance for Asian Paints due to urban demand challenges.
- ·NMDC's results are expected to provide insights into iron ore prices and demand trends.
VERIFIEDMint Markets·89d★ ON YOUR LIST
Mphasis to Glenmark - Jay Thakkar suggests 3 stocks to buy or sell for short-term in F&O segmentAI summary· NEGATIVE
- ·Gift Nifty indicates a lower opening for the Indian market, down 97 points at 23,882.
- ·Benchmark indices experienced a decline due to profit-taking and increasing crude oil prices.
- ·Nifty 50 is encountering resistance at 24,100 and support at 23,800.
Google News, India stocks·92d★ ON YOUR LIST
Stocks to Watch Today: TVS Motor, Exide Industries, Meesho, Groww, Gujarat Themis, Glenmark Pharma,... - Moneycontrol.comVERIFIEDMint Markets·94d★ ON YOUR LIST
Stocks to buy for short term: Glenmark Pharma, Manappuram Finance … Ajit Mishra of Religare Broking suggests 3 sharesAI summary· NEUTRAL
- ·Ajit Mishra of Religare Broking has identified three stocks for short-term gains.
- ·Glenmark Pharmaceuticals is among the stocks recommended.
- ·Manappuram Finance is also highlighted as a potential short-term investment.